KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zoetis (ZTS) Research & Development (2016 - 2025)

Zoetis (ZTS) has disclosed Research & Development for 12 consecutive years, with $199.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 6.99% to $199.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $698.0 million through Dec 2025, up 1.75% year-over-year, with the annual reading at $698.0 million for FY2025, 1.75% up from the prior year.
  • Research & Development for Q4 2025 was $199.0 million at Zoetis, up from $170.0 million in the prior quarter.
  • The five-year high for Research & Development was $199.0 million in Q4 2025, with the low at $118.0 million in Q1 2021.
  • Average Research & Development over 5 years is $152.2 million, with a median of $150.0 million recorded in 2022.
  • The sharpest move saw Research & Development increased 17.86% in 2021, then fell 3.09% in 2025.
  • Over 5 years, Research & Development stood at $138.0 million in 2021, then increased by 7.25% to $148.0 million in 2022, then rose by 17.57% to $174.0 million in 2023, then rose by 6.9% to $186.0 million in 2024, then increased by 6.99% to $199.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $199.0 million, $170.0 million, and $172.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.